Wereport a patient with pulmonary adenocarcinoma complicated by the syndromeof inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS). A 66-year-old womanwas diagnosed as having pulmonary adenocarcinoma with malignant pleural effusion following investigations for cough and dyspnea. After drainage of the effusion she received combination chemotherapy with CDDPand VDS. She developed SIADH 48 hours following chemotherapy. Interestingly, the use of carboplatin (CBDCA) and VDSin the subsequent treatment course was well tolerated indicating that the SIADHwas most likely to have been induced by administration of CDDP.
Introduction
The syndrome of inappropriate secretion of antidiuretic hormone(SIADH)is characterized by water retention, hyponatremia and central nervous system symptoms. SIADHhas various causes including central nervous system disorders, pulmonary or endocrine diseases, paraneoplastic syndromes and some drugs (1) (2) (3) (4) (5) . Anticancer agents such as vincristine and cyclophosphamide are well documented to induce SIADH (6-10) but cases of SIADHconsequent to cisplatin (CDDP) administration are rare (1 1-15) . In this report, wedescribe a patient with lung adenocarcinoma complicated by a malignant pleural effusion who developed SIADHfollowing chemotherapy with CDDP.Webriefly review the recent cases of SIADHresulting from CDDPadministration.
Case Report
A 66-year-old womanwas admitted to hospital with a 4 month history of dry cough and dyspnea. She was mildly anemic, neurologically intact and had clinical signs of a large left pleural effusion. Laboratory data on admission are shown in Table 1 . Chest radiography (Fig. 1A) and chest computed tomography (CT) ( On the third day of chemotherapy the patient developed nausea and general fatigue followed by a gradual disturbance of consciousness with convulsions. As indicated in Table 2, her serum sodium level had fallen to 122 mEq//. Plasma osmolarity was 264 mOsm/kg/H2Owhile her urine osmolarity was inappropriately high at 460 mOsm/kg/H2O. The patient was Plasma arginine vasopressin (AVP) concentration was 1.7 pg/ ml with no evidence of thyroid, adrenal or anterior pituitary dysfunction thereby indicating a diagnosis of SIADH.
The patient was treated with cautious hypertonic saline infusion, furosemide and fluid restriction together with oral demethylchlortetracycline hydrochloride (900 mg/day for 3 days) (16) (Fig. 2) . Her convulsions were resolved and she regained full consciousness. Her serum sodium level rose gradually and was 132 mEq// 72 hours later. reported SIADHfollowing CDDPadministration in a patient with malignant thymoma. The suggested potential mechanisms included central ADHrelease, acute tumor lysis with the consequent liberation of large quantities of ADHor potentiation of the peripheral action ofADH.The fact that the plasma ADH concentration in the present patient remained within normal limits suggests that the peripheral potentiation of ADHaction was involved. There is another possibility that the SIADHinduced by chemotherapeutic agents might be associated with overhydration carried out to prevent renal toxicity ( 1 8). Though Kurtzberg et al (19) described that CDDPmay inhibit the solute transport by the thick ascending limb of Henle, the mechanism of SIADHdue to CDDPinfusion is still unknown.
Some patients have developed convulsions associated with hyponatremia following CDDPadministration ( 1 1-1 5). Mead et al (12) described eight patients who experienced epileptic seizures while undergoing chemotherapy with agents containing CDDP. Severe hyponatremia, perhaps related to SIADH, was identified in two of these patients as a possible precipitating factor. In both patients, who had ovarian carcinoma, hyponatremia and convulsions occurred two days following the initiation of chemotherapy, which is a similar timescale as that seen in our patient. Pulmonary diseases such as pneumonia and pleuritis may result in SIADHby damaging the intrathoracic ADH-inhibitory vagal tracts that mediate the baroreceptor reflex via the intrathoracic space (20, 21) . Otsuka et al (20) also reported SIADHinduced by intrathoracic CDDPinfusion in a patient with pleuritis due to thymoma. In the present case, the presence of pleural effusion may induce pharmacokinetic changes of CDDP,due to prolonged retention of CDDPin pleural effusion (22) . Weconsidered that this prolonged retention of CDDP in the effusion might cause SIADH.
Maurer et al suggested that increased levels of human neurophysins are associated with SIADH. In fact, plasma concentrations of vasopressin-associated human neurophysin (VP-HNP)were elevated in patients with small-cell lung cancer, however, VP-HNPitself was considered to be indirectly responsible for SIADH (23) . Although, we did not measure this neurophysin, VP-HNPwas not associated with SIADHin our case, because elevated levels of VP-HNPin non-small-cell lung cancer were much less frequent (23).
In conclusion, although SIADHfollowing CDDPadministration is rare, electrolyte balance should be carefully monitored whensymptomsof SIADHare found throughout the clinical course of chemotherapy that includes CDDP.
